Adalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: The Research in Active Rheumatoid Arthritis (ReAct) trial

Gerd R. Burmester, Xavier Mariette, Carlomaurizio Montecucco, Indalecio Monteagudo-Sáez, Michel Malaise, Athanasios G. Tzioufas, Johannes W J Bijlsma, Kristina Unnebrink, Sonja Kary, Hartmut Kupper

Research output: Contribution to journal › Article › peer-review

Fingerprint Dive into the research topics of 'Adalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: The Research in Active Rheumatoid Arthritis (ReAct) trial'. Together they form a unique fingerprint.

Medicine & Life Sciences

Chemical Compounds